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ABSTRACT
Fifteen years elapsed between the discovery of the
double helix (1953) and the first DNA sequencing
(1968). Modern DNA sequencing began in 1977, with
development of the chemical method of Maxam and
Gilbert and the dideoxy method of Sanger, Nicklen
and Coulson, and with the first complete DNA
sequence (phage rX174), which demonstrated that
sequence could give profound insights into genetic
organization. Incremental improvements allowed
sequencing of molecules >200kb (human cytomeg-
alovirus) leading to an avalanche of data that
demanded computational analysis and spawned
the field of bioinformatics. The US Human Genome
Project spurred sequencing activity. By 1992 the
first ‘sequencing factory’ was established, and
others soon followed. The first complete cellular
genome sequences, from bacteria, appeared in 1995
and other eubacterial, archaebacterial and eukary-
otic genomes were soon sequenced. Competition
between the public Human Genome Project and
Celera Genomics produced working drafts of the
human genome sequence, published in 2001, but
refinement and analysis of the human genome
sequence will continue for the foreseeable future.
New ‘massively parallel’ sequencing methods are
greatly increasing sequencing capacity, but further
innovations are needed to achieve the ‘thousand
dollar genome’ that many feel is prerequisite to
personalized genomic medicine. These advances
will also allow new approaches to a variety of
problems in biology, evolution and the environment.
INTRODUCTION
The year 2007 marks the 30th anniversary of the
introduction of modern DNA sequencing methods (1,2)
and the ﬁrst complete sequence of a DNA molecule (3,4).
These 30 years have seen astounding growth in DNA
sequencing capacity and speed. From the ﬁrst small phage
genome, 5386 bases in length, DNA sequencing has
advanced to sequence the human genome of  3 billion
bases (5,6). The total amount of sequence in the databases
passed the 100 Gb mark in August 2005 (Figure 1). It is
remarkable that such progress has been made using
methods that are reﬁnements of the basic ‘dideoxy’
method introduced by Sanger in 1977.
THE SEQUENCE CONCEPT IN BIOLOGY
But the story of sequencing began more than a quarter
of a century earlier, when Sanger’s studies of insulin ﬁrst
demonstrated the importance of sequence in biological
macromolecules. That work showed, for the ﬁrst time,
that proteins are composed of linear polypeptides formed
by joining amino acid residues in a deﬁned, but apparently
arbitrary order (7,8). Summarizing these studies in his
1959 Nobel address (9), Sanger observed: ‘Examination of
the sequences of the two chains reveals neither evidence of
periodicity of any kind, nor does there seem to be any
basic principle which determines the arrangement of the
residues. They seem to be put together in an order that is
random, but nevertheless unique and most signiﬁcant,
since on it must depend the important physiological action
of the hormone.’
Consequently, when the double-helical structure of
DNA was proposed soon thereafter (10), it was natural
to consider its implications for base sequences in DNA.
In their original paper, Watson and Crick pointed out that
their structure placed no constraints on the sequence of
a DNA molecule. They also observed that it suggested a
mechanism for faithful replication of any base sequence.
Thus the stage was set for an attack on the coding
problem—how is the amino acid sequence of a protein
determined by the base sequence of the DNA gene that
encodes it? It is interesting that this inferred importance
of DNA sequence led to the solution of the coding
problem before the experimental determination of any
actual DNA sequences, but that is another story.
yA paper by Levy, S., Sutton, G., Ng, P.C., Feuk, L., Halpern, A.L., et al. titled ‘The Diploid Genome Sequence of an Individual Human’ appeared
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Fifteen years elapsed between the discovery of the DNA
double helix and the ﬁrst experimental determination of
a DNA sequence. This delay was caused by several factors
that made the problem intimidating:
(i) The chemical properties of diﬀerent DNA molecules
were so similar that it appeared diﬃcult to separate
them.
(ii) The chain length of naturally occurring DNA
molecules was much greater than for proteins and
made complete sequencing seems unapproachable.
(iii) The 20 amino acid residues found in proteins have
widely varying properties that had proven useful in
the separation of peptides. The existence of only
four bases in DNA therefore seemed to make
sequencing a more diﬃcult problem for DNA than
for protein.
(iv) No base-speciﬁc DNAases were known. Protein
sequencing had depended upon proteases that cleave
adjacent to certain amino acids.
Some RNA molecules did not share all of these
drawbacks with DNA. In particular, transfer RNA
molecules were small and individual types could be
puriﬁed. RNAases with base speciﬁcity were known so
methods analogous to those used in protein sequencing
could be developed. Consequently Escherichia coli alanine
tRNA was the ﬁrst nucleic acid molecule to be sequenced
by Holley and coworkers in 1965 (11). Unlike amino acid
sequences, which were not interpretable until 3D protein
structures were determined by X-ray crystallography,
models for the structure of tRNAs could be deduced
by assuming base pairing analogous to that found in the
DNA double helix.
The ﬁrst DNA molecule puriﬁed to homogeneity
was the genome of bacteriophage fX174, reported by
Sinsheimer in 1959 (12). Equilibrium buoyant density
centrifugation of the fX virion yielded pure preparations
from which the DNA could be easily isolated by phenol
extraction. fX DNA turned out to be a single-stranded
circular molecule that was estimated to be  5000nt
in length.
Puriﬁcation of other viral DNAs was also accomplished
soon, in particular phage lambda DNA (13), a linear
molecule with cohesive ends that was the subject of the
ﬁrst successful DNA sequencing. Wu and Kaiser (14,15)
measured incorporation of radiolabeled nucleotides by
E. coli DNA polymerase in reactions that extended the
30 termini to ﬁll in the complementary cohesive end
sequences. They reported a partial sequence in 1968, but
completion of the 12 base sequence was not accomplished
until 1971 (16). An inroad into DNA sequencing had been
made, but the method only applied to short stretches
near the ends of lambda and related phage genomes.
Wu also provided a means to generalize his approach by
introducing the use of oligonucleotide primers in DNA
sequencing reactions (17).
The next decisive event, without which DNA sequenc-
ing could not have proceeded along the path that it took,
was the discovery of type II restriction enzymes by
Hamilton Smith and coworkers (18,19). These enzymes
recognized and cleaved DNA at speciﬁc short nucleotide
sequences, typically 4–6bp in length. It was soon
found that enzymes recognizing many diﬀerent sequences
could be identiﬁed by screening bacterial strains (20).
The restriction enzymes therefore provided a general
method for cutting a large DNA molecule into a
number of smaller pieces that could be separated by
size using gel electrophoresis. These pieces had speciﬁc
ends that could function as starting points for the
sequencing methods that developed over the next few
years.
Early work on DNA sequencing that followed sequenc-
ing of the phage lambda cohesive ends used methods
similar to those used for RNA sequencing. These methods
employed base-speciﬁc chemical reactions such as depur-
ination, or enzymes with some degree of speciﬁcity, for
example E. coli endonuclease IV, to produce fragments
that were typically in the range of 10–20bp in length.
The size of the fragments that could be analyzed was
limited by the separation methods that were used. These
included 2D chromatography, and also electrophoresis
in one dimension followed by chromatography in a
second. When such a small fragment was incompletely
digested from one end by exonuclease then its sequence
could be determined by (i) analysis of the terminal
nucleotide of each partial digestion product or (ii) by
base-speciﬁc shifts in the position of the spot following
2D separation of the products.
Although these early methods were not powerful
enough to determine complete gene sequences, several
important regulatory signals were sequenced using them.
Examples are operator sequences from the E. coli lac
operon (21) and from phage lambda (22).
Figure 1. Growth of the nucleotide sequence database. The number of
published nucleotide sequences, and the total number of base pairs of
sequence are plotted versus the date of deposition or publication. Data
since 1981 are re-plotted from http://www.ncbi.nlm.nih.gov/Genbank/
genbankstats.html and data for sequences published before 1981 are
from Dayhoﬀ, Nucleic Acid Sequence Database, Vol. 1 (38). The dates
of landmark sequences and technological advances are indicated.
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In 1975, Sanger introduced his ‘plus and minus’ method
for DNA sequencing (23,24). This was a critical transition
technique leading to the modern generation of methods
that have completely dominated sequencing over the
past 30 years. The key to this advance was the use of
polyacrylamide gels to separate the products of primed
synthesis by DNA polymerase in order of increasing chain
length. The method analyzed the products of DNA
polymerase reactions that extended a primer annealed to
a single-stranded DNA template, as Wu and Kaiser had
done in sequencing the lambda cohesive ends. DNA
synthesis to extend the primer was carried out in two
sequential DNA polymerase reactions. The ﬁrst was
carried out under conditions where synthesis was slow
and asynchronous, resulting in a population of all possible
products extending 1,2,3,...up to a few hundred bases.
A
32P labeled nucleotide was incorporated at this step.
This product was then divided into eight aliquots and used
to prime a second round of DNA polymerase reactions.
In these reactions, synthesis was terminated in a sequence-
speciﬁc manner by supplying only one of the four
nucleoside triphosphates (‘plus’ reactions), or else three
of the four (‘minus’ reactions). The eight reactions were
electrophoresed in adjacent lanes of a 12% acrylamide,
8M urea denaturing gel. Following electrophoresis the gel
was placed in contact with X-ray ﬁlm for a suitable time,
typically overnight. When the ﬁlm was developed,
molecules diﬀering by a single nucleotide in length could
be resolved as discrete bands on the resulting autoradio-
graph. This allowed a sequence of  50 bases to be
deduced in a single experiment. The main problem with
the method is the diﬃculty in determining the length of
homopolymer runs. Bands corresponding to the beginning
and end of such runs are produced, but no bands are
produced for positions internal to runs, so run lengths
must be estimated from band spacing in the gel. This
becomes unreliable for longer runs. Nevertheless, the
plus and minus method was used to produce a complete
sequence of the fX DNA genome (3). In this
work, restriction fragments of double-stranded fX
replicative form DNA were melted and annealed to
single-stranded virion DNA to serve as speciﬁc primers
for the method.
Maxam and Gilbert (2) developed a DNA sequencing
methodthatwas similartotheSangerandCoulsonmethod
in using polyacrylamide gels to resolve bands that
terminated at each base throughout the target sequence,
but very diﬀerent in the way that products ending in
a speciﬁc base were generated. Their method started with
a double-stranded DNA restriction fragment radiolabeled
atoneendwith
32P.Thefragmentwasthencleavedbybase-
speciﬁc chemical reactions. One reaction cleaves at
both purines (the ‘A+G’ reaction), one preferentially
at A (‘A>G’), one at pyrimidines (‘C+T’) and one at
cytosines only (‘C’). Unlike the plus and minus method, the
chemical method produced bands for every sequence
position, including those within homopolymer runs. This
advantage ledto early widespread adoption ofthe chemical
method following its publication in February 1977 (2)
The problems with the plus and minus method were
solved when Sanger developed ‘the dideoxy method’ and
published it in December 1977 (1). The underlying
concept was to use chain-terminating nucleotide analogs
rather than subsets of the four natural dNTPs to cause
base-speciﬁc termination of primed DNA synthesis. In the
original implementation both arabinoside triphosphates
and 20,30-dideoxy nucleoside triphosphates were tried.
These analogs are incorporated in a sequence-speciﬁc
manner by E. coli Pol I, but the enzyme is unable to further
extend the growing DNA strand (in the case of the ddNTPs
simply because of the lack of a 30 hydroxyl group).
Synthesis was carried out in the presence of all four
dNTPs, one of which was a-
32P labeled. Four reactions
were set up, each doped with a chain-terminating analog of
one of the dNTPs, at an appropriate concentration. If the
concentration of ddATP, for example, was adjusted so that
it was incorporated in place of the normal dATP  1% of
the time then a series of chain-terminated products were
produced, each ending with an A. Some molecules in the
product ended at each of the A residues in the sequence.
When such a product was electrophoresed on a denaturing
12% acrylamide gel, a series of bands representing the
positions of all A’s in the sequence were displayed. Unlike
the plus and minus method, bands were produced for each
A within runs of consecutive A residues. When the four
dideoxy reactions were run in adjacent lanes it was possible
to read sequences of  100nt in most cases.
The dideoxy sequencing method as originally described
required a single-stranded DNA template. The general
applicability of the method was therefore greatly enhanced
when Messing and collaborators developed methods for
cloning into the single-stranded phage M13 (25–27).
SEQUENCES, SEQUENCES, SEQUENCES
The complete sequence of fX determined by the plus and
minus method was published in 1977 and then revised
slightly in 1978 after resequencing by the dideoxy method.
It was a revelation because, to the surprise of many,
it turned out to be extremely interesting. Unlike amino
acid sequences of proteins, the DNA sequence of the fX
genome could be interpreted to tell a fascinating story
based upon interpretation of the sequence in terms of the
genetic code. Analysis of mutations in genes identiﬁed by
traditional phage genetics, combined with amino acid
sequence information for protein components of the
fX virion, allowed phage genes to be located on the
DNA sequence. For the ﬁrst time translation of a DNA
sequence in all possible reading frames identiﬁed long
open reading frames that could be assigned to genes
identiﬁed by traditional genetic methods. And, most
surprising, it was clear that signiﬁcant portions of the
genome were translated in more than one reading frame
to produce two diﬀerent protein products. These pairs
of ‘overlapping genes’ had not been detected by recombi-
nation mapping of the fX genome but their existence was
indisputable when the sequence was analyzed in light of
genetic and protein sequence information (28,29).
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quickly in 1978 (30). Sequencing had begun by determin-
ing sequences of RNA copies of parts of the genome,
but was rapidly completed after publication of the
Maxam–Gilbert method.
With the introduction of the gel-based sequencing
methods, the rate of DNA sequencing accelerated
(Figure 1). Progress in the methodology was incremental
and was driven by the selection of sequencing targets of
increasing complexity. In the Sanger group, the 16.5kb
human mitochondrial genome (31) was followed by the
48.5kb complete phage lambda genome (32). Following
Sanger’s retirement his prote ´ ge ´ Bart Barrell led sequencing
of the 172kb Epstein–Barr virus (33) and then the
237kb human cytomegalovirus genome (34). For 15
years following fX, the sequencing group at the MRC
Laboratory of Molecular Biology in Cambridge, UK, had
continuously held the record for the longest DNA
sequence published.
During this period the useful read length of dideoxy
sequencing increased from about 100 up to about 400.
This improvement was mainly the result of: (i) the use of
very thin sequencing gels and (ii)
35S labeling of the DNA,
which gives sharper bands than
32P due to the lower
energy of the emitted b particles. Sequencing capacity was
also increased by the use of gels with narrow lanes,
typically 48 lanes on a 20 by 45cm gel. Sequencing
reactions could be done manually in 96-well plates with
handheld repetitive pipetting devices. During this period
a single person could run 8 gels on a single day, each with
12 sequence ladders, and obtain some 30kb of primary
sequence data. But it was diﬃcult to do this more than
about twice a week.
THE BIRTH OF BIOINFORMATICS
Beginning with fX, the management and analysis
of sequencing data became a major undertaking. The
original fX data was in the notebooks of nine diﬀerent
workers each concerned with particular portions of the
molecule. Michael Smith, on sabbatical in the Sanger
group, had a brother-in-law named Duncan McCallum
who was a business computer programmer in Cambridge.
He wrote the ﬁrst programs to help with the compilation
and analysis of DNA sequence data (in COBOL) (35).
We each transcribed our manually deduced sequences
onto paper forms, which then were entered in blocks of 60
on punched cards. The programs then (i) compiled and
numbered the complete sequence, (ii) allowed the editing
of a previously compiled sequence, (iii) searched the
sequence for speciﬁc short sequences or families of
sequences, for example restriction sites and (iv) translated
the sequence in all reading frames. Though invaluable, the
programs did not produce output suitable for publication,
so the original ﬁgure displaying the fX sequence with its
genes and their translation products annotated (3) was
hand typed by Peggy Dowding. Roger Staden helped with
computer analysis of the original fX sequence and quickly
wrote the ﬁrst suite of programs meant to be interactive
and ‘designed speciﬁcally for use by people with little or
no computer experience’ (36). These programs developed
into the Staden Package, still in use today (37).
With the proliferation of DNA sequence data, came the
need for a DNA sequence database. Margaret Dayhoﬀ
was the early pioneer in this area. She had previously
established a protein sequence database and published the
ﬁrst collection of nucleotide sequence information in 1981
(38). Shortly thereafter, in 1982 GenBank was created by
the NIH to provide a ‘timely, centralized, accessible
repository for genetic sequences’ (39).
As the sequence databases grew, methods to compare
and align sequences soon became a rate-limiting step in
the analysis of sequence data. The development of rapid
search programs such as FASTA (40) and BLAST (41)
made it practical to identify genes in a new sequence by
comparison to all sequences already in the databases.
These are just a few of the early developments in
the computer analysis of DNA sequence information.
Bioinformatics has developed into a full-blown dis-
cipline far beyond the scope of a review such as this.
Bioinformatics is central to the interpretation of sequence
data and to the generation of testable hypotheses arising
from such data.
THE JOHN HENRY SYNDROME
Toward the end of the manual-sequencing era, the ﬁrst
generation of ‘automated sequencers’ appeared. These
machines did not initially automate much of the sequenc-
ing process. Gels were still prepared manually, and loaded
manually. Only the readout of the sequence data was
really automated and in the beginning the base-calling
algorithms were quite unsatisfactory. Many steeped in the
traditions of manual sequencing were doubtful that
automation could compete with dedicated graduate
student sequencers. The next few years would show how
wrong we were.
AUTOMATED SEQUENCING FACTORIES
In 1986 the laboratory of Leroy Hood at Caltech, in
collaboration with Applied Biosystems (ABI), published
the ﬁrst report of automation of DNA sequencing (42).
This initial report showed that sequencing data could be
collected directly to a computer without autoradiography
of the sequencing gel. Although the method could, in
principle, have been applied to the chemical sequencing
method, the dideoxy method was chosen. A sequencing
primer was ﬂuorescently end labeled using four diﬀerent
dyes. A diﬀerently labeled primer was used in each of the
four dideoxy sequencing reactions. The reactions were
combined and electrophoresed in a single polyacrylamide
tube gel. DNA was observed by ﬂuorescence as it passed
a detector near the bottom of the gel and the four dyes
were distinguished by their colors. Fluorescence data was
continuously recorded and stored by a computer over
the course of a typical 13h run. The sequence could be
deduced from the order in which the four diﬀerent dyes
passed the detector. Work at ABI developed programs to
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sequence (43).
The ABI 370A DNA sequencer appeared very shortly,
and was ﬁrst used to determine the sequence of a gene by
Craig Venter and colleagues at NIH (44). At NIH, Venter
set up a sequencing facility with six automated sequencers
and two ABI Catalyst robots. In 1992 Venter established
The Institute for Genomic Research (TIGR) to expand
his sequencing operation and established a facility with
30 ABI 373A automated sequencers and 17 ABI Catalyst
800 robots (45). The organizational diﬀerences between
this facility and the manual sequencing projects that
preceded it were as important as the use of automation.
This was a real factory with teams dedicated to diﬀerent
steps in the sequencing process such as template prepara-
tion, gel pouring and sequencer operation. Data analysis
was integrated into the process so that problems in earlier
steps could be detected and corrected as soon as possible.
By contrast, in the CMV project, each participating
investigator sequenced a region of the genome single-
handedly.
An early demonstration of the power of automated
sequencing was the development of the expressed sequence
tag (EST) approach to gene discovery. In this approach
cDNA copies of messenger RNA were cloned at random
and subjected to automated sequencing. In the ﬁrst report
from Venter and colleagues in 1991, 337 new human genes
were reported, 48 homologous to genes from other
organisms (46). This initial study was expanded to an
analysis of 83 million nucleotides of cDNA sequence that
identiﬁed fragments of more than 87000 human cDNA
sequences, more than 77000 of which were previously
unknown (47). This approach was adopted by many
genome projects. Today the EST database contains over
43 million ESTs from over 1300 diﬀerent organisms.
Another early application of the automated sequencer
was the worm genome sequencing project (see below)
which was underway by 1992 with the beginning elements
of a factory atmosphere as well (48).
In 1993 the Sanger Centre, later renamed the Wellcome
Trust Sanger Institute, was established by the Wellcome
Trust and the Medical Research Council. This is arguably
the most important of the sequencing centers established
to participate in the worldwide public eﬀort to sequence
the human genome. Located in Hinxton, near Cambridge,
‘the Sanger’ is an outstanding example of a modern
sequencing center. The facility has produced  3.4 10
9
bases of ﬁnished sequence by the 30th anniversary of the
dideoxy sequencing method.
CELLULAR GENOMES
Until 1995 the only completely sequenced DNA molecules
were viral and organelle genomes. That year Craig
Venter’s group at TIGR, and their collaborators, reported
complete genome sequences of two bacterial species,
Haemophilus inﬂuenzae (49) and Mycoplasma genitalium
(50). The H. inﬂuenzae sequence gave the ﬁrst glimpse
of the complete instruction set for a living organism.
The M. genitalium sequence showed us an approximation
to the minimal set of genes required for cellular life.
The methods used to obtain these sequences were as
important for subsequent events as the biological insights
they revealed. Sequencing of H. inﬂuenzae introduced
the whole genome shotgun (WGS) method for sequencing
cellular genomes. In this method, genomic DNA is
fragmented randomly and cloned to produce a random
library in E. coli. Clones are sequenced at random and the
results are assembled to produce the complete genome
sequence by a computer program that compares all of the
sequence reads and aligns matching sequences. Sanger and
colleagues used this general strategy to sequence the
lambda phage genome (48.5kb), published in 1982.
However, no larger genome was shotgun sequenced until
H. inﬂuenzae (1.83Mb). In the interim shotgun sequencing
was used extensively, but only to sequence mapped
subclones of larger sequences. This was the strategy used
for the 230kb human CMV sequence, the largest sequence
ﬁnished sequencing before the H. inﬂuenzae genome.
Venter and colleagues introduced critical improve-
ments that made it feasible, for the ﬁrst time, to shotgun
sequence complete cellular genomes. Perhaps most impor-
tant was adoption of the ‘paired ends’ strategy (51,52).
The automated sequencing procedure used in the H.
inﬂuenzae project used melted double-stranded DNA
as template, whereas the HCMV project had used single-
stranded M13 vectors. With double-stranded templates it
was convenient to sequence each clone from both ends.
Because the randomly sheared DNA was carefully sized
before cloning, the distance between the reads from the
ends of each clone could be estimated. The assembly
program used this information to construct ‘scaﬀolds’
from the blocks of completely overlapped sequence
(‘contigs’). When two contigs contained sequences from
opposite ends of a single clone, then the two contigs could
be linked, although a ‘sequence gap’ was said to exist
between them. Sequence gaps remaining at the end of the
shotgun phase of sequencing could be closed by sequenc-
ing from a primer for a site internal to a clone bridging the
gap. Gaps between scaﬀolds are ‘physical gaps’ that
contain sequences, which do not occur within any of the
sequenced clones. Other measures, such as PCR between
the ends of scaﬀolds using a genomic DNA template, were
used to close physical gaps.
Another critical factor in the application of shotgun
sequencing to cellular genomes was the TIGR assembler.
Previous assembly programs were not designed to handle
thousands of sequence reads involved in even the smallest
cellular genome projects. However, the TIGR assembler
that had been designed to assemble vast amounts of EST
data was adequate for the job.
Once these initial sequences were reported the ﬂood-
gates were open and a steady stream of completed genome
sequences has been appearing ever since. It is only possible
here to touch on a few of the most signiﬁcant. Because
of the large communities of scientists actively engaged
in studies that would beneﬁt from the availability of
a genome sequence I have chosen to mention the bacteria
E. coli and Bacillus subtilis, the yeast Saccharomyces
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ﬂy Drosophila melanogaster and humans.
Because of its position as the pre-eminent model
organism of molecular biology, sequencing of the
genome of E. coli (4.6Mb) was proposed by Blattner as
early as 1983 (53). Sequencing proceeded as sequencing
technology improved, starting with manual methods
and ﬁnishing in 1997 with automated sequencers (54).
Early sequences covering  1.9Mb, were deposited starting
in 1992, and were obtained from an overlapping set
of cosmid clones. The ﬁnal  2.5Mb was obtained
by shotgun sequencing of  250Kb I-Sce I fragments.
This E. coli genome sequence, along with several other
strains sequenced subsequently has yielded a wealth of
information about bacterial evolution and pathogenicity
(55,56).
Meanwhile, another model for large-scale genome
sequencing projects had emerged; the international con-
sortium. The ﬁrst genome sequence to be completed by
this approach was the yeast S. cerevisiae (12.0Mb) (57), in
late 1996. This was the also the ﬁrst eukaryotic organism
to be sequenced. The project involved about 600 scientists
in Europe, North America and Japan. The participants
included both academic laboratories and large sequencing
centers.
The next success of the consortium approach was the
genome of the bacterium B. subtilis (4.2Mb) (58), in 1997.
The project began in 1990 with the participation of
ﬁve European laboratories. The project ﬁnally became a
consortium of 25 laboratories in six European countries
coordinated at the Institut Pasteur by Frank Kunst
(coordinator) and Antoine Danchin. A consortium of
seven Japanese laboratories, coordinated by Naotake
Ogasawara and Hiroshi Yoshikawa at the Nara Institute
of Science and Technology, Japan, also participated, as
well as one Korean and two US laboratories.
The ﬁrst animal genome sequenced was that of ‘the
worm’ C. elegans (97Mb) (59), in 1998. The authorship
of this work was simply ‘The C. elegans Sequencing
Consortium’, which was a collaboration between the
Washington University Genome Sequencing Center in the
United States and the Sanger Centre in UK.
In 1996, ABI introduced the ﬁrst commercial DNA
sequencer that used capillary electrophoresis rather than a
slab gel (the ABI Prism 310), and in 1998 the ABI Prism
3700 with 96 capillaries was announced. For the ﬁrst time
DNA sequencing was truly automated. The considerable
labor of pouring slab gels was replaced with automated
reloading of the capillaries with polymer matrix. Samples
for electrophoresis were automatically loaded from
96-well plates rather than manually loaded as the previous
generation of sequencers had been. Celera Genomics was
found by Applera Corporation (the parent company of
ABI) and Craig Venter in May 1998 to exploit these new
machines by applying Venter’s methods for WGS
sequencing to the human genome, in direct competition
with the publicly funded Human Genome Project. Celera
acquired 300 of the machines, each capable of producing
1.6 10
5 bases of sequence data per day, for a total
theoretical capacity of  5 10
7 bases of raw sequence
data per day.
Celera chose the D. melanogaster genome to test the
applicability of the WGS approach to a complex
eukaryotic genome (60). This involved a scientiﬁc collab-
oration between the scientists at Celera and those of
the Berkeley and European Drosophila Genome Projects.
These projects ﬁnished 29Mb of the 120Mb of euchro-
matic portion of the genome. (About one-third of the
180Mb Drosophila genome is centromeric heterochroma-
tin.) Using the WGS approach, data was collected over
a 4-month period that provided more than 12  coverage
of the euchromatic portion of the genome. The results
validated the data produced by the ABI 3700s, the
applicability of the WGS approach to eukaryotic gen-
omes, and the assembly methods developed at Celera
(61). This was a nearly ideal test case because the WGS
data could be analyzed separately and then portions of
it could be compared with ﬁnished sequence already
produced by the Drosophila Genome Projects. At the same
time the sequence information provided a valuable
resource for Drosophila genetics. More than 40 scientists
at an ‘Annotation Jamboree’ did initial annotation of
the sequence. These scientists, mainly drawn from the
Drosophila research community, met at Celera for a2-week
period to identify genes, predict functions, and begin a
global synthesis of the genome sequence information.
SEQUENCING OF THE HUMAN GENOME
Eventual sequencing of the human genome became an
imaginable goal at the outset of the sequencing era
30 years ago. Formal discussions of the idea began in
1985 when Robert Sinsheimer organized a meeting on
human genome sequencing at the University of California,
Santa Cruz (62). That same year Charles DeLisi and
David A. Smith commissioned the ﬁrst Santa Fe
conference, funded by the DOE, to study the feasibility
of a Human Genome Initiative. Discussions continued
and in 1988 reports recommending a concerted genome
research program were issued by committees of the
congressional Oﬃce of Technology Assessment and the
National Research Council. In 1990 the DOE and NIH
presented a joint 5-year US Human Genome Project plan
to Congress. It was estimated that the project would take
15 years and cost  3 billion US$.
The US Human Genome Project established goals of
mapping, and in some cases sequencing, several model
organisms as well as humans. These included E. coli,
yeast (S. cerevisiae), the worm (C. elegans), drosophila
(D. melanogaster) and mouse (laboratory strains of Mus
domesticus). So, several of the sequences discussed above
received funding from the Human Genome Project. The
publicly funded eﬀort became an international collabora-
tion between a number of sequencing centers in the United
States, Europe and Japan. Each center focused sequencing
eﬀorts on particular regions of the genome, necessitating
detailed mapping as a ﬁrst step. In 1994, a detailed genetic
map of the human genome was published including
5840 mapped loci with a mean spacing of 0.7cM
(1 centiMorgan =  10
6bp) (63). In 1998 the public
project, now in a race with Celera, also adopted the new
6232 Nucleic Acids Research, 2007, Vol. 35, No. 18ABI Prism 3700 capillary sequencers. In 1999 the Human
Genome Project celebrated passing the billion base-pair
mark, and the ﬁrst complete sequence of a human
chromosome was reported [chromosome 22 (64)].
Meanwhile at Celera, human genome sequencing was
underway using the WGS strategy. Human genome
sequencing began in September 1999 and continued until
June 2000, when data collection was completed and
an initial assembly was achieved. The Celera data
provided approximately 5-fold coverage of the genome.
An additional 3-fold coverage of unordered and
unoriented BAC sequences from the public eﬀort
was included in the assembly. The power of the WGS
strategy was amply demonstrated.
On 25 June 2000at the White House, President Clinton
with Prime Minister Tony Blair publicly announced draft
versions of the human genome sequence from both the
publicly funded project and from Celera. In February
2001 the Celera (5) and the public (6) draft human genome
sequences were published the same week in Science and
Nature. The race was oﬃcially a tie, but it was clear to all
that the entry of Celera had speeded the process by several
years. Both projects ended up needing the other to make
the progress that was made. The Celera assembly beneﬁted
from data produced in the public project and the public
project quickly adopted some of Celera’s methods, in
particular the paired-end strategy. Celera’s basic methods
have now been adopted by all publicly funded genome
projects.
Sequencing of the human genome captured public
attention in a way that is extremely rare for a scientiﬁc
topic. Several books for the general public have centered
around the ‘race’ for the human genome sequence (65,66).
Leaders of the public and the private projects have even
published books describing events from their own
personal perspectives (67,68).
BEYOND THE HUMAN GENOME
The major purpose of this review is to commemorate the
beginning of the DNA sequencing era with a discussion
of the early history of sequencing. But a brief summary
of current directions and future horizons is useful to allow
an appreciation of the long-term implications of those
historical events. It has been said that a full understanding
of the human genome sequence may take the better part
of the 21st century. Perhaps ironically, the major tool
currently available for achieving this understanding
is DNA sequencing, on a scale much larger than in the
past. Also, we have entered an era where very large-scale
DNA sequencing provides a feasible approach to a
multitude of problems concerning biology, disease and
the environment. This review will conclude with an
overview of these developments.
NEXT GENERATION SEQUENCING TECHNOLOGY
In the last few years methods have emerged, which for the
ﬁrst time challenge the supremacy of the dideoxy method.
The common feature of these methods is that they are
‘massively parallel’, meaning that the number of sequence
reads from a single experiment is vastly greater than the
96 obtained with modern capillary electrophoresis-based
Sanger sequencers. At present this very high throughput
is achieved with substantial sacriﬁces in length and
accuracy of the individual reads when compared to
Sanger sequencing. Nonetheless, assemblies of such data
can be highly accurate because of the high degree of
sequence coverage obtainable. The methods are designed
for projects that employ the WGS approach. They are
most readily applied to resequencing, in which sequence
data is aligned with a reference genome sequence in order
to look for diﬀerences from that reference. A few examples
of speciﬁc instruments that employ massively parallel
strategies are discussed below. Other technologies are
under development (69–75), and all of these methods will
undoubtedly continue to improve.
The ﬁrst of the massively parallel methods to become
commercially available was developed by 454 Life
Sciences (76) and is based on the ‘pyrosequencing’
technique (77,78). This system allows shotgun sequencing
of whole genomes without cloning in E. coli or any host
cell. First DNA is randomly sheared and ligated to linker
sequences that permit individual molecules captured on
the surface of a bead to be ampliﬁed while isolated within
an emulsion droplet (79). A very large collection of such
beads is arrayed in the 1.6 million wells of a ﬁber-optic
slide. As with the Sanger method, sequencing is carried
out using primed synthesis by DNA polymerase. The
array is presented with each of the four dNTPs,
sequentially, and the amount of incorporation is mon-
itored by luminometric detection of the pyrophosphate
released (hence the name ‘pyrosequencing’). A CCD
imager coupled to the ﬁber-optic array collects the data.
In sequencing across a homopolymer run, the run length is
estimated from the amount of pyrophosphate released,
which is proportional to the number of residues incorpo-
rated. Errors that result from misjudging the length
of homopolymer runs result in single-base insertions
and deletions (indels). These constitute the major source
of errors in 454 data. The ‘plus and minus’ method of
Sanger and Coulson had this same diﬃculty. Nonetheless,
the second generation 454 Genome Sequencer FLX is
reportedly able to produce 100Mb of sequence with
99.5% accuracy for individual reads averaging read over
250 bases in length.
Another promising technique is the Solexa technology
(80,81). A key diﬀerence between this method and the 454
is that it uses chain-terminating nucleotides. The ﬂuo-
rescent label on the terminating base can be removed to
leave an unblocked 30 terminus, making chain termination
a reversible process. The method reads each base in a
homopolymer run in a separate step and therefore does
not produce as many indels within such runs as the 454.
Because the reversible dye terminator nucleotides are not
incorporated eﬃciently, the read length of the Solexa
method is less than for 454. Also more base-substitution
errors are observed due to the use of modiﬁed polymerase
and dye terminator nucleotides. The method sequences
clusters of DNA molecules ampliﬁed from individual
fragments attached randomly on the surface of a ﬂow cell.
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analyzed, the machine can reportedly produce 1 billion
bases (1Gb) of 30–40 base sequence reads in a single run.
Applied Biosystems is also developing a massively
parallel sequencer, its Supported Oligonucleotide
Ligation and Detection system (SOLiD). The technology
is based on a hybridization-ligation chemistry (73). The
sample preparation aspect of this technology including
library preparation, clonal ampliﬁcation of the target
DNA by emulsion PCR on beads is very similar to the 454
processes in principle. However, the size of the beads used
for emPCR (1mm versus 26mm) and the array format
(random versus ordered) are diﬀerent. These diﬀerences
aﬀord the SOLiD technology the potential of generating a
signiﬁcantly higher density sequencing array (potentially
over a few hundred fold higher), as well as more ﬂexibility
in terms of sample input format. The sequence interroga-
tion is done through the repeated cycles of hybridization
of a mixture of sequencing primers and ﬂuorescently
labeled probes, followed by ligation of the sequencing
primers and the probes, then the detection of the
ﬂuorescent signals on the probes which encode the bases
that are being interrogated. Although it has a short read
length of about 25–35, it can generate  2–3Gb of
sequence per run.
During the development of these new technologies
it may be useful to combine sequence data obtained
using diﬀerent techniques. Combination of 454 data with
a smaller amount of capillary sequencing data has been
shown to be cost-eﬀective in certain situations (82).
Similarly, the combination of Solexa data with a smaller
amount of 454 data could be eﬀective. The 454 data would
provide longer read lengths and a method for obtaining
paired end sequences from long DNA fragments to greatly
aid assembly (83).
Massively parallel methods of the type described
above are likely to dominate high-throughput sequencing
applications for the next few years. However, a variety
of other approaches are being investigated that may
eventually develop into practical methods. Several of
these approaches, for example ‘nanopore sequencing’,
have been reviewed (71,84).
GENOMIC MEDICINE
All disease has a genetic basis, whether in genes inherited
by the aﬀected individual, environmentally induced
genetic changes that produce a cancer, or the genes of a
pathogen and their interaction with those of the infected
individual. This emerging ﬁeld of genomic medicine
cannot be considered in detail here, but is the subject of
several reviews (85–87). Sequencing of the human genome
as well as all major pathogens is beginning to have a major
impact on the diagnosis, treatment and prevention
of diseases. Genome sequences have provided potential
targets for drug therapy (88,89) as well as vaccine
candidates (90,91).
An era of personalized medicine, informed by informa-
tion concerning the patient’s genotype, has been widely
predicted. The Holy Grail in this ﬁeld has become ‘the
$1000 genome’ sequence. To stimulate work in this area
the X Prize Foundation has established the $10 million
Archon X Prize for Genomics (92) (http://genomics.
xprize.org/).
METAGENOMICS
Only a very small fraction of the microbes found in nature
have been grown in pure culture. Consequently we lack
a comprehensive view of the genetic diversity to be found
on Earth. An approach to this problem has emerged called
‘metagenomics’ or ‘environmental genomics’ (93,94).
DNA is isolated directly from environmental samples
and sequenced, without attempting to culture the organ-
isms from which it comes.
Early studies using manual DNA sequencing methods
focused on 16S rRNA genes as a gauge of phylogenetic
diversity (95). High-throughput sequencing methods
make shotgun sequencing of the whole metagenome
from environmental samples informative. A study of the
DNA isolated from an acid-mine bioﬁlm yielded nearly
complete genome sequences for two organisms and partial
sequences for three others from just 76.2Mb of data (96).
Studies of the more complex environment of the oceans
have shed new light on the diversity of life on Earth.
A total of more than 1.6Gb of sequence from Sargasso
Sea samples yielded 1.2 million previously unknown gene
sequences, only about one-third of which were recogniz-
able homologs of previously known genes (97). Before
analysis of the Sargasso Sea data the NCBI non-
redundant amino acid (nraa) dataset contained some 1.5
million peptides, about 630000 of which were classiﬁed as
bacterial. In an expanded study, ocean samples were
collected during an expedition from the North Atlantic
through the Panama Canal and into the South Paciﬁc.
Shotgun sequencing of these samples produced a dataset
of 7.7 million sequence reads yielding 6.3Gb of sequence
(98–101). More than 6 million proteins are predicted from
this global ocean sampling (GOS) data. These include
members of almost all previously known prokaryotic
protein families. When these GOS data were clustered
with all previously known protein sequences, about 4000
out of a total of 17000, medium and large clusters
contained only GOS sequences (101). The metagenomic
approach is being applied to study microbial populations
in many environments, for example the human gut (102).
A diﬃculty with current metagenomic sequence datasets
from complex microbial communities is that the vast
majority of the data cannot be assembled. This is mainly
due to the fact that the cost of acquiring enough
sequencing data for the full assembly of all or most of
the organisms present in any given sample is still
prohibitively high using the state-of-the-art Sanger-based
sequencing technology. The development of strategies to
apply the new massively parallel sequencing methods may
solve this problem if the sequence read length and the
accuracy of these technologies can be dramatically
improved. In the meantime, another approach is the
sequencing of individual cells isolated from the environ-
ment. Substantial progress toward this goal has been
6234 Nucleic Acids Research, 2007, Vol. 35, No. 18achieved (103,104). It is clear that the metagenomic
approach is becoming a major new tool for understanding
our environment. It will also provide a vast array of new
genes for application in the emerging ﬁeld of synthetic
biology.
WHAT NEXT?
The amount of nucleotide sequence in the databases has
increased logarithmically by nine orders of magnitude
over the 40-year period from 1965 to 2005 (Figure 1). This
amounts to an average doubling time of about 16 months.
Upon closer inspection, the logarithmic rate of increase is
not quite constant over time. Inﬂection in the curve
(Figure 1) appear to correspond to technical innovations,
such as the development of the gel-based sequencing
techniques 30 years ago, and the introduction of automa-
tion. This suggests that we are about to see another
inﬂection in the curve resulting from the next generation
of massively parallel sequencers.
In 1977 it was possible to imagine a benchtop machine
that could sequence the E. coli genome in a few days
(although it could only be seen as a black box). The
sequencing factory would have been almost inconceivable
because it was at odds with the whole culture of biological
research. But the sequencing factory did come to pass, and
with it came vast amounts of data ideally suited for
computational analysis. Taken at face value, the 16-month
doubling time for the sequence database is substantially
faster than the 24-month doubling in computer power
predicted by Moore’s law (105) (http://www.intel.com/
technology/mooreslaw/). Even if these trends continue
it seems unlikely that this diﬀerence could begin to limit
sequence data collection in the near term. However, some
common problems in the analysis of sequence data are
already rate-limiting steps in research. A prime example
is all-against-all sequence comparison, which requires
a computation time that increases with the square of the
amount of sequence data. It appears possible that
methods for collecting sequence data could soon outstrip
our capacity to adequately analyze that data. At present a
sizable bioinformatics core is an essential part of a
sequencing center. The currently popular vision that an
investigator with a single benchtop machine could replace
a large sequencing center can only be realized with
increases in the productivity of computers and bioinfor-
maticians even more dramatic than that expected for
sequencers. It appears that for our individual $1000
genome sequences to be truly useful, fundamental
advances in computation and bioinformatics will be
essential. The obvious importance of computational
analysis of sequence data has led to a greater overall
appreciation of the role of theory in biology. A relation-
ship between theory and experiment, not unlike that found
in 20th century physics, seems to be taking shape.
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